A federal judge in Delaware ruled that two separate juries will decide the damages in a case involving three patents for coronary stents made by Johnson & Johnson subsidiary Cordis Corp. and Boston Scientific Corp., after the companies agreed to a $716 million settlement last week.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Boston Scientific settles Cordis stent war for $716 million
Boston Scientific Corp. agreed to shell out $716 million to settle 14 patent infringement suits with Cordis Corp., closing a major front in the stent wars.
The Natick, Mass.-based medical device giant said it will pay the settlement in cash using a reserve set aside for one of the lawsuits.
Cordis appeals $23 million jury verdict in stent-cutting suit
Cordis Corp. and a co-defendant appealed a jury verdict awarding Spectralytics Inc. $22.5 million in a laser stent-cutting patent infringement suit.
Cordis and Norman Noble Inc. filed the appeal in the U.S. Court of Appeals for the Federal Circuit. Spectralytics had sued the pair in July 2005 in the U.S. District Court for Minnesota, alleging infringement of a patent for a “Laser Cutting Tool for Cutting Elongated Hollow Workpieces.”
Viacor co-founder, Cleveland Clinic doc joins Endovalve board
A prominent Ohio cardiologist with ties to Massachusetts is joining the board of Endovalve, a New Jersey-based mitral valve repair firm, MedCity News reported.
Marc Gillinov, head of the Cleveland Clinic’s Center for Atrial Fibrillation and a co-founder of Wilmington, Mass.-based Viacor, was named to Endovalve’s scientific advisory board.
Boston Scientific takes a beating at TCT meeting
It looks as though Boston Scientific Corp. might have left its heart (and some business) in San Francisco.
To say its been a rough week at the annual Transcatheter Cardiovascular Therapeutics meeting would be a grotesque understatement, as the Natick-based coronary stent colossus suffered a series of high-profile setbacks at the annual meeting of thousands of cardiologists from around the world.
Cordis, Wyeth sue Abbott, Boston Scientific over coatings patent
Cordis Corp. and Wyeth sued a pair of medical device giants, Abbott and Boston Scientific Corp., alleging infringement of a coatings patent for coronary stents.
It’s the latest chapter in the never-ending stent wars, which have seen a number of lawsuits and settlements in recent months.
Cordis Corp.’s small Cypher stent lands FDA approval
A small version of Cordis Corp.‘s Cypher drug-eluting stent won approval from the Food & Drug Administration for treating blockages in small blood vessels.
The Bridgewater, N.J.-based Johnson & Johnson subsidiary said the federal watchdog’s approval of its 2.25mm Cypher sirolimus-eluting coronary stent was based on a quartet of studies comparing it to bare-metal stents.
Boston Scientific: Hey, the Taxus ain’t so bad
Boston Scientific Corp. returned fire to Medtronic and Abbott, aiming to counter the rivals’ claims that their stents outperform BoSci’s older Taxus model.
Abbott: Xience V is better than Taxus, too
Abbott threw another grenade Boston Scientific‘s way with a study showing its Xience V drug-eluting stent outperforms BoSci’s Taxus.
The news follows a Medtronic study that company touted earlier today, showing that its Endeavor stent is safer than the Taxus.
Medtronic: Endeavor stent is safer than BoSci’s Taxus
Medtronic Inc. lobbed another grenade in the ongoing stent wars, touting a long-term study it says shows that its Endeavor drug-eluting stent is safer than rival Boston Scientific Corp.‘s Taxus.
Medtronic said the three-year results from the Endeavor IV trial comparing its zotarolimus‐eluting stent and BoSci’s paclitaxel‐eluting stent in 1,548 patients show a nearly 50 percent reduction in the risk of heart attack or cardiac death with the Endeavor stent.
Boston Scientific: 1,500 patients enrolled in Promus Element stent trial
Boston Scientific Corp. enrolled more than 1,500 patients in the Platinum clinical trial of its Promus Element drug-eluting stent, two months ahead of schedule, setting the stage for approval applications to the Food & Drug Administration and the Japanese Ministry of Health, Labor and Welfare.
The Natick, Mass.-based medical devices giant said the workhorse trial is a global, randomized, pivotal controlled study of its platinum chromium Promus Element everolimus-eluting stent involving 1,532 patients at more than 140 sites worldwide.